

LAB_057 Insulin Tolerance Test in Mice (Expiry: Oct 2029)

I. OBJECTIVE

To describe the general procedural expectation for performing safe, effective, and humane insulin tolerance tests (ITT) in mice.

II. DEFINITIONS

Competent - “the consistent application of knowledge and skill to the standard of performance required regarding the care and use of animals. It embodies the ability to transfer and apply knowledge and skill to new situations and environments.” (NHMRC, 2013).

Insulin Tolerance Test (ITT) – A test performed to evaluate insulin sensitivity by monitoring glucose clearance from the blood over time following administration of an injection of insulin. Poor sensitivity to insulin results in a reduced rate of glucose clearance. As a research tool, this test is useful in studying diseases such as metabolic syndrome and diabetes mellitus.

International Unit (IU) – in pharmacology, this is a standardised unit of measurement relative to the expected effect, as compared to the mass of a substance. For insulin, IU is the most commonly used unit of measurement.

High Fat Diet (HFD) - A diet which contains 45-60% fat, as compared to standard rodent chow diet, which contains ~10% fat.

III. COMMENTS / RECOMMENDATIONS

- Relative to animal ethics applications, when using this SOP, the following must be described in the individual ethics application: insulin type and dose, method of blood collection, and any intended variation to this SOP.
- ITT data outcomes, and reproducibility of these results, are significantly influenced by suboptimal and inconsistent procedures. It is critically important for the scientific validity of data obtained that ITT is well planned, and performed in a precise and controlled manner, as outlined in this SOP, and summarised within textbox 1, within the reference information section.
- Matching of animal-groups is an important consideration as age, sex, strain, body weight, reproductive status, and health status, among others animal characteristics, are all known to influence insulin sensitivity and glucose tolerance.
- Stress significantly impacts glucose metabolism. The test environment should be managed as a “low stress” environment, free from uncontrolled external stimuli such as human traffic, unnecessary noise, and intense lighting. It is recommended in the days to weeks prior to commencing experimentation that the mice are trained to tunnel handling or other low-stress handling techniques by the person/s that will be completing the ITT. This period of acclimatisation will enable more efficient handling, and reduced stress for the mice throughout the procedure (Gouveia *et al.*, 2017; Henderson *et al.*, 2020).
- All other stimuli must be controlled as much as possible. For example, light/dark cycles, animal feed, ventilation, caging systems, and environmental enrichment should all be standardised. Note: glucose clearance is variable dependent on by time of day, and light/dark phase (Carroll *et al.*, 1973; la Fleur *et al.*, 2001); study design should account for, and aim to control, this potential variability.
- “Diseased” or “sick” mice (i.e. animals with any symptoms, exposure history, or diagnostic results which indicate sub-optimal health) should not be used within ITT procedures, unless that disease state is considered part of the study design (e.g. pharmaceutically induced diabetes mellitus, phenotypic SOD1 mice).

Conditions:

- Investigators named in an animal ethics application, relative to this SOP, must be competent to implement the SOP
- Any variation to this SOP must be described in the relevant animal ethics application
- If this SOP has not been reviewed and approved by a UQ AEC within the last three years it is no longer valid and cannot be used in animal ethics applications until reapproved (see “AEC Reviewed/Approved” date in this document’s header).

- The type and dose rate of insulin administered must be established relative to the experimental design. Note, the different types of insulin are not interchangeable, they often require different doses and will cause different rates and duration of glucose clearance. In laboratory animal research, literature commonly cites the use of short-acting insulin (e.g., Actrapid®, Humulin®). In this setting short-acting insulin is often dosed at 0.5 – 0.75IU/kg. This dose rate should be calibrated relative to the individual mouse's characteristics, including gross body mass, or lean body mass (for obese animals), any expected insulin resistant (e.g., from type II diabetes mellitus) or strain differences.
- Fasting is a standard component of ITT. Prior to insulin administration mice are usually fasted for 2-6 hours (NB: fasting from food only, mice are still permitted free access to water). Fasting for >6 hours increases the risk of critical hypoglycaemia and should be avoided in this procedure. Where fasting >6 hrs is intended to occur for the purpose of performing ITT, the reviewing AEC will expect specific justification as to why this variation is required and why it should be considered ethically acceptable.
- Generally, anaesthetic agents should not be used to facilitate ITT as their use can potentially lead to confounding of experimental data.

IV. EQUIPMENT

- Personal Protective Equipment (PPE)
Requirements vary dependent on facility and the type of work being conducted.
- Permanent Marker
- Disinfectant (e.g. 70% ethanol)
- Electronic weigh scales
- Local anaesthetic ointment (e.g. Emla® cream)
- Heat source, e.g. heat mat, regulated warming box, or warm water bath,
- Clean restraint tubes (appropriate size and type)
- Venepuncture instrument/tool, e.g. sterile lancet, number 11 scalpel blade, 25 - 30G needle
- Blood collection tubes (if not collecting blood directly onto the glucose test strip)
- Timer / stopwatch or clock
- Insulin stock solution (e.g. Actrapid 100 IU/mL, diluted in sterile saline to 1IU/mL)
- Insulin syringes (with 25-30G needle swaged)
- Gauze swabs
- Glucometer and compatible glucose test strips
- Sharp's container and clinical waste bin
- 10-25% Glucose solution (sterile, innocuous vehicle e.g. saline or PBS) <on hand for use in the event of critical hypoglycaemia>

V. PREPARATION

- Check AEC approvals, procedural documents, and animal identification, to ensure that the correct animals and procedures (including personnel and location details) have been selected for the scheduled work.
- Ensure appropriate experimental record sheets are organised (see table 1 for an example template, within the reference information section).
- Ensure the glucometer is functioning appropriately and 'ready to go' (e.g. there are sufficient numbers of compatible test strips available, and the device has sufficient battery charge).
- Establish what should occur in the event of critical hypoglycaemia, e.g., immediate euthanasia vs. therapeutic treatment with glucose.

Conditions:

- Investigators named in an animal ethics application, relative to this SOP, must be competent to implement the SOP
- Any variation to this SOP must be described in the relevant animal ethics application
- If this SOP has not been reviewed and approved by a UQ AEC within the last three years it is no longer valid and cannot be used in animal ethics applications until reapproved (see "AEC Reviewed/Approved" date in this document's header).

VI. PROCEDURE

1. Measure and record the gross body weight of each mouse. Animals may be marked at the base of the tail using the permanent marker to assist with identification.

Animal handling is performed in accordance with [LAB_006 Handling and Hand-Held Restraint in Mice and Neonates](#).

2. Place the mice in a clean cage with routine access to water, but no access to food. Commence fasting of the mice for 2 to 6 hrs (see comments/ recommendations for guidance on fasting duration).
3. Measure and record gross body weight of each mouse, post fasting.

At this time topical local anaesthetic ointment (e.g. Emla® cream) may be applied to the venepuncture site and the mice may be warmed, as per the relevant blood collection SOP, listed under step 5

4. Calculate and record the amount of insulin to be administered to each animal, relative to body weight.

- ITT, insulin (Actrapid) dose = 0.5 – 0.75 IU/kg

To achieve 0.5IU/kg body mass, using 1IU/mL insulin stock solution

Volume of insulin stock solution for injection (µL) = 0.5(IU) x body weight(kg) / 1(IU/mL)

For example, a 25g mouse will require an injection volume of 12.5µL

Ensure injection volumes calculated do not exceed the maximum limits as prescribed within the relevant SOPs, listed under step 6.

5. Restrain the first mouse as required and collect a blood sample as per the approved procedure in the ethics application. This initial blood sample is used to measure and record the fasting basal glucose level. Blood samples are collected directly onto a glucose test strip for immediate assessment. Alternatively, a capillary tube or other blood collection tube may be used.

Following any blood collection method, ensure the collection site has stopped bleeding. If ongoing bleeding is observed gentle pressure using a gauze swab should be applied.

6. Immediately following step 5, administer the predetermined insulin dose (identified in step 4), via [LAB_028 Injections - Intra-peritoneal \(IP\) in Mice, Rats and Neonates](#).

7. Record the time of blood collection and insulin administration (from steps 5 and 6, respectively) as the “start time” on the experimental record sheet (and start a timer accordingly).

Often multiple mice will be undergoing ITT on the one day, at the same time. Careful time management is required to ensure the blood collection points are accurately reflective of the scheduled time points for each mouse. As such, individual animals should be staggered (e.g., using 1–5-minute intervals).

8. Monitor animals for hypoglycaemia (through to step 12) and if observed take immediate action to either a) immediately euthanise the animal/s, or b) administer therapeutic treatment using glucose.

Critical hypoglycaemia is recognisable by any of the following symptoms: weakness, lethargy, apathy, tremors, heightened anxiety, loss of consciousness, seizure/convulsions; or a blood glucose level <2mmol/L (<36mg/dL).

- a) immediate euthanasia – as per any of the methods approved in your ethics application
- b) therapeutic treatment with glucose, via [LAB_028 Injections - Intra-peritoneal \(IP\) in Mice, Rats and Neonates](#).

This ‘rescue’ intervention is only appropriate if the animal’s wellbeing is not compromised and if the animal has significant value for use in subsequent testing (e.g. subsequent behavioural testing).

Glucose dose = 0.5 – 1 mg/g

To achieve 1mg/g body mass, using 20% glucose solution:

Conditions:

- Investigators named in an animal ethics application, relative to this SOP, must be competent to implement the SOP
- Any variation to this SOP must be described in the relevant animal ethics application
- If this SOP has not been reviewed and approved by a UQ AEC within the last three years it is no longer valid and cannot be used in animal ethics applications until reapproved (see “AEC Reviewed/Approved” date in this document’s header).

 <p>THE UNIVERSITY OF QUEENSLAND AUSTRALIA CREATE CHANGE</p>	<p>UQ Animal Ethics Committee - Standard Operating Procedure</p> <p>LAB_057 Insulin Tolerance Test in Mice</p> <p>Institutional author: Mater Research-UQ</p> <p>AEC Reviewed and Approved: October 2026</p> <p>SOP Expiry: October 2029</p>	<p>Version #3.0</p> <hr/> <p>Page 4 of 7</p>
---	--	--

Volume of glucose solution for injection (mL) = 1(mg) x body weight(g) / 200(mg/mL)

For example, a 25g mouse will require an injection volume of 125µL

Ensure injection volumes calculated do not exceed the maximum limits as prescribed within the relevant SOPs, listed under step 6.

If critical hypoglycaemia occurs within the model respond immediately as described above and then refer to guidance, relative to unexpected adverse events, provided on the [animal ethics webpage](#).

9. Collect serial blood samples at predetermined timepoints post insulin administration. Ensure each timepoint and sample result is recorded on the experimental record sheet.
 - a) These timepoints for blood collection generally include: 15, 30, 45, 60, 90, 120 minutes post insulin administration.
 - b) The predetermined timepoints may vary between individual models, however, the number of blood collection points should not exceed 10 in total (inclusive of the initial blood collection for establishing the fasting basal glucose level);
 - c) Collection volumes at each timepoint should remain <10µL;
Larger blood volumes may be collected (e.g. 20µL) so long as the following point is observed (relative to total blood volume collected);
 - d) The total volume of blood collected must be the minimum amount required for the project and should not exceed a “moderate bleed” (see table 2, within the reference information section).

Blood collection in rodents almost always causes some “wastage” (e.g. oozing or dripping of blood post venepuncture, extravasation of blood into the subcutaneous space). It is critical that this volume of wastage is estimated and accounted for when estimating the total blood loss to the animal.

10. At the end of the experiment return mice to their home cages with food and water and monitor their general behaviour and physical condition. If any signs of pain and distress are observed take immediate action as appropriate – for guidance refer to the [animal ethics webpage](#).
11. Reassess the mice after at least 1 hour, before returning to routine monitoring protocols.
It is recommended that these animals are then permitted at least a 24hr “respite” period, where they are not used for other procedures.
12. After the ITT procedure, stored blood samples may be assessed further using various assays (ex vivo). This testing may require specific blood handling and storage (e.g. collection of blood plasma and storage at ≤ (-)20°C, until analysis).

VII. REFERENCE INFORMATION

TEXTBOX 1 | Summary of General Experimental Considerations, relative to ITT and Glucose Tolerance Test (GTT) (image source: Benedé-Ubieto *et al.*, 2020). *In the context of this SOP, please consider the following comments:*

- “same gender”, should be considered to read as “sex matched”
- minimum animal numbers per group, should be established based on power analysis
- *GTT is not considered part of this SOP. For information relative to this procedure please refer to [LAB_05f Glucose Tolerance Test \(GTT\) in Mice](#).*

Conditions:

- Investigators named in an animal ethics application, relative to this SOP, must be competent to implement the SOP
- Any variation to this SOP must be described in the relevant animal ethics application
- If this SOP has not been reviewed and approved by a UQ AEC within the last three years it is no longer valid and cannot be used in animal ethics applications until reapproved (see “AEC Reviewed/Approved” date in this document’s header).

TABLE 1 | Example experimental record sheet for conducting ITT.

Mouse ID#	BW (g)	Insulin (μL)*	Time of glucose injection	Glucose levels (mg/dL)						
				0min	15min	30min	45min	60min	90min	120min

*Insulin type: _____, and concentration _____ (IU/mL)

TABLE 2 | Recommended blood collection volumes based on a mouse's live body weight (NHMRC 2008).

The total amount of blood loss from any blood collection procedure must take into account the sample volume collected as well as any circumstantial bleeding (e.g. prolonged bleeding post venepuncture).

Mouse Weight	TOTAL BLOOD VOLUME (TBV) [equates to 5-7% of body weight]	Minor bleed (<7.5% of TBV)	Moderate bleed (7.5-10% of TBV)	Major Bleed (10-15% of TBV)
Recovery period required between bleeds, relative to volume collected:		1 week recovery	2 weeks recovery	3 weeks recovery
18g	1.2mL	<90uL	90-120uL	120-180uL
22g	1.5mL	<115uL	115-150uL	150-225uL
26g	1.8mL	<140uL	140-180uL	180-270uL

VIII. BIBLIOGRAPHY

Andrikopoulos S, Blair A, Deluca N, Fam BC, and Proietto J (2008). Evaluating the glucose tolerance test in mice. *Am J Physiol E11docri110I Metab.* 295(6):EI323-32

Ayala, J. E., Samuel, V. T., Morton, G. J., Obici, S., Croniger, C. M., Shulman, G. I., Wasserman, D. H., McGuinness, O. P., & NIH Mouse Metabolic Phenotyping Center Consortium (2010). Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. *Disease models & mechanisms*, 3(9-10), 525–534.
<https://doi.org/10.1242/dmm.006239>

Conditions:

- Investigators named in an animal ethics application, relative to this SOP, must be competent to implement the SOP
- Any variation to this SOP must be described in the relevant animal ethics application
- If this SOP has not been reviewed and approved by a UQ AEC within the last three years it is no longer valid and cannot be used in animal ethics applications until reapproved (see "AEC Reviewed/Approved" date in this document's header).

 <p>THE UNIVERSITY OF QUEENSLAND AUSTRALIA</p> <p>CREATE CHANGE</p>	<p>UQ Animal Ethics Committee - Standard Operating Procedure</p> <p>LAB_057 Insulin Tolerance Test in Mice</p> <p>Institutional author: Mater Research-UQ</p> <p>AEC Reviewed and Approved: October 2026</p> <p>SOP Expiry: October 2029</p>	<p>Version #3.0</p> <hr/> <p>Page 6 of 7</p>
--	--	--

Benedé-Ubieto, R., Estévez-Vázquez, O., Ramadori, P., Cubero, F. J., & Nevzorova, Y. A. (2020). Guidelines and Considerations for Metabolic Tolerance Tests in Mice. *Diabetes, metabolic syndrome and obesity: targets and therapy*, 13, 439–450. <https://doi.org/10.2147/DMSO.S234665>

Carroll FK, Nestel PJ; Diurnal Variation in Glucose Tolerance and in Insulin Secretion in Man. *Diabetes* 1 May 1973; 22 (5): 333–348. <https://doi.org/10.2337/diab.22.5.333>

Gouveia, K., Waters, J. & Hurst J. (2017) Mouse Handling Tutorial. National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs). <https://nc3rs.org.uk/3rs-resources/mouse-handling/mouse-handling-tutorial>, accessed June 2022.

Henderson, L.J., Dani, B., Serrano, E.M.N. *et al.* (2020). Benefits of tunnel handling persist after repeated restraint, injection and anaesthesia. *Sci Rep* 10, 14562 <https://doi.org/10.1038/s41598-020-71476-y>

Heikkinen S, Argmann CA, Champy MF, Auwerx J. (2007). Evaluation of glucose homeostasis. *Curr. Protoc. Mol. Biol.* Chapter 29, Unit 29B 23. [PubMed: 18265403]

International Mouse Phenotyping Consortium. Intraperitoneal glucose tolerance test (IPGTT). IMPC. <https://www.mousephenotype.org/>. accessed June 2022.

Jørgensen, M. S., Tornqvist, K. S., & Hvid, H. (2017). Calculation of Glucose Dose for Intraperitoneal Glucose Tolerance Tests in Lean and Obese Mice. *Journal of the American Association for Laboratory Animal Science : JAALAS*, 56(1), 95–97.

Kwankaew J, Saetung S, Chanprasertyothin S, Leelawattana R, Rattarasarn C. Lean mass inversely predicts plasma glucose levels after oral glucose load independent of insulin secretion or insulin sensitivity in glucose intolerance subjects. *Endocr J.* 2014;61(1):77-83. doi: 10.1507/endocrj.ej13-0241. Epub 2013 Oct 22. PMID: 24152998.

la Fleur S, Andries Kalsbeek, Joke Wortel, Madelon L. Fekkes, Ruud M. Buijs; A Daily Rhythm in Glucose Tolerance: A Role for the Suprachiasmatic Nucleus. *Diabetes* 1 June 2001; 50 (6): 1237–1243. <https://doi.org/10.2337/diabetes.50.6.1237>

Nagy C, Einwallner E. Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT). *J Vis Exp.* 2018 Jan 7;(131):56672. doi: 10.3791/56672. PMID: 29364280; PMCID: PMC5908452

National Mouse Metabolic Phenotyping Center, Louise Lantier, Vanderbilt MMPC (Ed) (2018) Oral Gavage Glucose Tolerance Test (OGTT) accessed June 2022.

NHMRC. (2008). Guidelines to Promote the Wellbeing of Animals Used for Scientific Purposes: The Assessment and Alleviation of Pain and Distress in Research Animals. National Health and Medical Research Council (NHMRC). Retrieved from <https://www.nhmrc.gov.au/about-us/publications/guidelines-promote-wellbeing-animals-used-scientific-purposes>

NHMRC. (2013). Australian code for the care and use of animals for scientific purposes. National Health and Medical Research Council (NHMRC). Retrieved from <https://www.nhmrc.gov.au/about-us/publications/australian-code-care-and-use-animals-scientific-purposes>

Pacini, G., Omar, B., & Ahren, B. (2013). Methods and models for metabolic assessment in mice. *Journal of diabetes research*, 2013, 986906. <https://doi.org/10.1155/2013/986906>

Pedro PF, Tsakmaki A, Bewick GA. The Glucose Tolerance Test in Mice. *Methods Mol Biol.* 2020;2128:207-216. doi: 10.1007/978-1-0716-0385-7_14. PMID: 32180195.

Conditions:

- Investigators named in an animal ethics application, relative to this SOP, must be competent to implement the SOP
- Any variation to this SOP must be described in the relevant animal ethics application
- If this SOP has not been reviewed and approved by a UQ AEC within the last three years it is no longer valid and cannot be used in animal ethics applications until reapproved (see "AEC Reviewed/Approved" date in this document's header).

 <small>THE UNIVERSITY OF QUEENSLAND AUSTRALIA</small> <small>CREATE CHANGE</small>	UQ Animal Ethics Committee - Standard Operating Procedure LAB_057 Insulin Tolerance Test in Mice Institutional author: Mater Research-UQ AEC Reviewed and Approved: October 2026 SOP Expiry: October 2029	Version #3.0
		Page 7 of 7

Small L, Ehrlich A, Iversen J, Ashcroft SP, Trošt K, Moritz T, Hartmann B, Holst JJ, Treebak JT, Zierath JR, Barrès R. Comparative analysis of oral and intraperitoneal glucose tolerance tests in mice. *Mol Metab.* 2022 Mar;57:101440. doi: 10.1016/j.molmet.2022.101440. Epub 2022 Jan 11. PMID: 35026435; PMCID: PMC8810558.

Thrivikraman KV, Huot RL, Plotsky PM. Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat. *Brain Res Brain Res Protoc.* 2002 Oct;10(2):84-94. doi: 10.1016/s1385-299x(02)00185-x. PMID: 12431707.

Vinué Á, González-Navarro H. Glucose and Insulin Tolerance Tests in the Mouse. *Methods Mol Biol.* 2015;1339:247-54. doi: 10.1007/978-1-4939-2929-0_17. PMID: 26445794.

Virtue S, Vidal-Puig A. GTTs and ITTs in mice: simple tests, complex answers. *Nat Metab.* 2021 Jul;3(7):883-886. doi: 10.1038/s42255-021-00414-7. PMID: 34117483.

This SOP deserves notable reference and acknowledgement of original authorship by Dr Tim Biffin –Animal Ethics Veterinary Officer, UQ, with review and updates in 2026 by Hon Professor Josephine Forbes – Mater Research Institute-UQ, and Dr Rink-Jan Lohman – School of Pharmacy and Pharmaceutical Sciences.

Version #	Reviewing AEC	AEC Review Date	Outcome
2.0	Anatomical Biosciences AEC, Health Sciences AEC, Molecular Biosciences AEC and Laboratory Biomedicine AEC	01/12/2022	Approved to 01/12/2025 In March 2025, Approval Extended to March 2026
3.0	Anatomical Biosciences AEC, Health Sciences AEC, Molecular Biosciences AEC and Laboratory Biomedicine AEC	Various meeting dates across October 2026	Approved to October 2029

Conditions:

- Investigators named in an animal ethics application, relative to this SOP, must be competent to implement the SOP
- Any variation to this SOP must be described in the relevant animal ethics application
- If this SOP has not been reviewed and approved by a UQ AEC within the last three years it is no longer valid and cannot be used in animal ethics applications until reapproved (see "AEC Reviewed/Approved" date in this document's header).